Talazoparib
Brand names: Talzenna · Active ingredient: Talazoparib Tosylate
In short: TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patie
What is Talazoparib used for?
TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-authorized companion diagnostic for TALZENNA .
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with:
•metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test .
•
metastatic androgen pathway modulation-naĂŻve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA-authorized test .
Talazoparib dosage
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Select patients for the treatment of advanced breast cancer with TALZENNA based on the presence of germline BRCA mutations .
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
Select patients for the treatment of HRR gene-mutated mAPMR or mAPMN/S prostate cancer with TALZENNA based on the presence of alterations in genes directly or indirectly involved in HRR (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C) .
Information on the FDA-authorized tests for the detection of genetic mutations is available at http://www.fda.gov/companiondiagnostics.
The recommended dosage of TALZENNA is 1 mg orally once daily, until disease progression or unacceptable toxicity.
The recommended dosage of TALZENNA is 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity.
Refer to the enzalutamide prescribing information for recommended enzalutamide dosing information.
Patients receiving TALZENNA and enzalutamide should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
Take TALZENNA with or without food .
Swallow TALZENNA capsules whole. Do not open or dissolve.
If a patient vomits or misses a dose of TALZENNA, instruct them to take the next prescribed dose at the usual time.
To manage adverse reactions, consider interruption of treatment with or without dose reduction based on severity and clinical presentation. Recommended dose reductions are indicated in Table 1 and Table 2. Treatment with TALZENNA should be permanently discontinued if more than 3 dose reductions are required.
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Dose Reductions | Dose Level
Recommended starting dose | 1 mg once daily
First dose reduction | 0.75 mg once daily
Second dose reduction | 0.5 mg once daily
Third dose reduction | 0.25 mg once daily
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
Dose Reductions | Dose Level
Recommended starting dose | 0.5 mg once daily
First dose reduction | 0.35 mg once daily
Second dose reduction | 0.25 mg once daily
Third dose reduction | 0.1 mg once daily
Refer to the enzalutamide prescribing information for dose modifications for adverse reactions associated with enzalutamide.
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer; HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
Monitor complete blood counts monthly and as clinically indicated . …
How to take Talazoparib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
•
MDS/AML: Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. This may be a sign of hematological toxicity or a more serious uncommon bone marrow problem called MDS or AML, which have been reported in patients who received PARP inhibitors .
•
Myelosuppression: Advise patients that TALZENNA may affect hematopoiesis and can cause anemia, leukopenia/neutropenia, and/or thrombocytopenia .
•
Administration Instructions: Advise patients that TALZENNA can be taken once daily with or without food. Instruct patients that if they miss a dose of TALZENNA, they should take their next normal dose at the usual time. Also advise patients to swallow each capsule whole, and that capsules must not be opened or dissolved .
•
Embryo-Fetal Toxicity: Advise females to inform their healthcare provider if they are pregnant or become pregnant. …
Warnings & precautions
Do not take this medicine if: None.
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA.
In clinical studies, among 1,096 patients treated with TALZENNA as a single agent or as part of a combination regimen with enzalutamide, the cumulative incidence of MDS/AML was approximately 1% including 0.6% with fatal outcomes. The incidence of MDS/AML among patients treated with active control or with placebo in combination with enzalutamide was 0.2%. The median duration of therapy with TALZENNA in patients who developed MDS/AML was approximately 2.8 years (range: 1 to 5.8 years).
Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA.
Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia has been reported in patients treated with TALZENNA .
Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 39%, 21%, and 15% of patients receiving TALZENNA as a single agent. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 0.7%, 0.3%, and 0.3% of patients.
Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 49%, 19%, and 9% of patients receiving TALZENNA in combination with enzalutamide. Forty-one percent of patients required a red blood cell transfusion, including 25% who required more than one transfusion. …
Talazoparib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Myelodysplastic Syndrome/Acute Myeloid Leukemia
•Myelosuppression
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to single agent TALZENNA among the 286 patients enrolled in the EMBRACA trial, TALZENNA 0.5 mg daily with enzalutamide in 511 patients enrolled in the TALAPRO-2 trial that included 197 patients with HRR gene-mutated mAPMR prostate cancer, and TALZENNA 0.5 mg daily with enzalutamide in 299 patients with HRR gene-mutated mAPMN/S prostate cancer enrolled in the TALAPRO-3 trial. Among the 810 patients with prostate cancer, 68% were exposed for greater than 1 year, 52% were exposed for greater than 2 years, and 35% were exposed for greater than 3 years. In this safety population, the most common (≥20%) adverse reactions including laboratory abnormalities were decreased hemoglobin (86%), decreased neutrophils (68%), decreased lymphocytes (62%), decreased platelets (54%), fatigue (48%), decreased albumin (26%), decreased calcium (26%), back pain (24%), decreased appetite (22%), and nausea (21%). …
Drug interactions
Effect of P-gp Inhibitors
Breast Cancer
Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, and verapamil. If coadministration of TALZENNA with these P-gp inhibitors cannot be avoided, reduce the dose of TALZENNA . When the P-gp inhibitor is discontinued, increase the dose of TALZENNA .
Coadministration of TALZENNA with these P-gp inhibitors increased talazoparib concentrations , which may increase the risk of adverse reactions.
Monitor for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with other P-gp inhibitors .
HRR Gene-Mutated mAPMR and mAPMN/S Prostate Cancer
The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor .
Effect of Breast Cancer Resistance Protein (BCRP) Inhibitors
Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a BCRP inhibitor . …
About this medicine
Talazoparib is an inhibitor of mammalian polyadenosine 5'-diphosphoribose (ADP-ribose) polymerase (PARP) enzymes. TALZENNA contains talazoparib tosylate. The chemical name of talazoparib tosylate is (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one 4-methylbenzenesulfonate (1:1). The chemical formula of talazoparib tosylate is C26H22F2N6O4S, and the relative molecular mass is 552.56 Daltons. The chemical structure of talazoparib tosylate is shown below:
Talazoparib tosylate is a white to yellow solid. TALZENNA capsules for oral use are available as liquid-filled soft gelatin capsules. Each capsule contains 0.1 mg, 0.25 mg, 0.35 mg, 0.5 mg, 0.75, or 1 mg of talazoparib equivalent to 0.145 mg, 0.363 mg, 0.509 mg, 0.727 mg, 1.09 mg, or 1.453 mg talazoparib tosylate, respectively.
TALZENNA capsules contain the following inactive ingredients: gelatin, glycerol, iron oxide (red), iron oxide (yellow), polyethylene glycol 400, purified water, sorbitol, titanium dioxide, and tocopherol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c6fd147f-a77e-4a0b-9280-e82ecc41b4be. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate